Nicholas R Adams
Nicholas R Adams
About
Detail
Lead Director, Strategy & Partnerships @ CVS Health | Chicago Booth MBA | Ex-Accenture, Walmart
New York, United States
Nicholas Adams is a proven leader in healthcare transformation, operations strategy, and large-scale program delivery. He has led enterprise-wide initiatives across some of the world’s largest organizations, with deep cross-industry experience spanning academic medical centers and hospitals, healthcare payers, pharmacy, retail, and financial services.
His expertise includes business planning, opportunity underwriting, and the identification and operationalization of strategic initiatives. His portfolio encompasses new product and service commercialization and payer access/authorization strategies; sourcing optimization and manufacturer relations; care coordination and site-of-service transitions; omni-channel transformation and community outreach; market analysis; compliance and risk mitigation; and technology and human capital enablement.
A hands-on general manager, Nick drives programs from initial concept to successful deployment – leveraging technology, advanced analytics, and deep stakeholder collaboration to design operating models, develop novel platforms and services, and deliver world-class performance in dynamic and highly competitive markets.
He brings a problem-solving philosophy grounded in customer- and patient-centric ideation, hypothesis-driven strategic design, and data-driven execution – enabling innovative service models, lean operations, and scalable, sustainable solutions.
Nick holds an MBA from the University of Chicago Booth School of Business, a BS from Georgetown University’s Walsh School of Foreign Service, and project and product management certificates from Cornell University.
Current Focus:
Nick is currently leading the development and operationalization of a first-of-its-kind, health-system-based care model aimed at engineering seamless care delivery, establishing sustainable reimbursement and economic frameworks, and expanding patient access to groundbreaking standard-of-care and investigational therapies in partnership with New York-Presbyterian Hospital, Columbia University Irving Medical Center, and Weill Cornell Medical Center.
The model supports a diverse range of next-generation therapies – including CAR T, TIL, bispecific antibodies, antisense oligonucleotides (ASOs), and gene therapies – with curative potential across high-impact disease states in oncology, hematology, neurology, ophthalmology, dermatology, and endocrinology.
His expertise includes business planning, opportunity underwriting, and the identification and operationalization of strategic initiatives. His portfolio encompasses new product and service commercialization and payer access/authorization strategies; sourcing optimization and manufacturer relations; care coordination and site-of-service transitions; omni-channel transformation and community outreach; market analysis; compliance and risk mitigation; and technology and human capital enablement.
A hands-on general manager, Nick drives programs from initial concept to successful deployment – leveraging technology, advanced analytics, and deep stakeholder collaboration to design operating models, develop novel platforms and services, and deliver world-class performance in dynamic and highly competitive markets.
He brings a problem-solving philosophy grounded in customer- and patient-centric ideation, hypothesis-driven strategic design, and data-driven execution – enabling innovative service models, lean operations, and scalable, sustainable solutions.
Nick holds an MBA from the University of Chicago Booth School of Business, a BS from Georgetown University’s Walsh School of Foreign Service, and project and product management certificates from Cornell University.
Current Focus:
Nick is currently leading the development and operationalization of a first-of-its-kind, health-system-based care model aimed at engineering seamless care delivery, establishing sustainable reimbursement and economic frameworks, and expanding patient access to groundbreaking standard-of-care and investigational therapies in partnership with New York-Presbyterian Hospital, Columbia University Irving Medical Center, and Weill Cornell Medical Center.
The model supports a diverse range of next-generation therapies – including CAR T, TIL, bispecific antibodies, antisense oligonucleotides (ASOs), and gene therapies – with curative potential across high-impact disease states in oncology, hematology, neurology, ophthalmology, dermatology, and endocrinology.
Contact Nicholas regarding:
work
Full-time jobs